894
Views
84
CrossRef citations to date
0
Altmetric
Research Article

Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) – a 20-year review: Can we do better?

, , , , , , & show all
Pages 537-541 | Received 03 Mar 2010, Accepted 16 May 2010, Published online: 22 Jun 2010

References

  • World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994;124 (Suppl):96–107.
  • World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. World Federation of Neurology 1998 (http://www.wfnals.org/).
  • Mitchell JD, O'Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2006;7:67–71.
  • Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review). In: The Cochrane Library, 1, 2007.
  • King SJ, Duke MM, O'Connor BA. People living with ALS/MND tell the diagnosis story: what happened before they knew. Amyotroph Lateral Scler. 2006;7(Suppl 1):34–6.
  • Department of Health. The National Service Framework for long-term conditions. Department of Health (2005).
  • Motor Neurone Disease Association. Standards of care to achieve quality of life for people affected by motor neuron disease (2004).
  • Mitchell JD, O'Brien MR. Centre Report – The MND Care Facility, Preston, UK. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:355–6.
  • Mitchell JD, Houghton E, Rostron G, Wignall C, Gatt JA, Phillips TM, . Serial studies of free radical and antioxidant activity in motor neuron disease and the effect of selegiline. Neurodegeneration. 1995;4:233–5.
  • Mitchell JD, Gatrell AC, Al-Hamad A, Davies RB, Batterby G. Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and south Cumbria. J Neurol Neurosurg Psychiat. 1998;65:842–7.
  • Donaghy C, Dick A, Hardiman O, Patterson V. Timeliness of diagnosis in motor neuron disease: a population-based study. Ulster Medical Journal. 2008;77:18–21.
  • Househam E, Swash M. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? Journal of the Neurological Sciences. 2000;180:76–81.
  • O'Brien M, Whitehead B, Mitchell D, Callagher P, Jack B. Descriptive audit of the key characteristics of the current MND population in a large UK specialist MND clinic. Amyotroph Lateral Scler. 2008;9(Suppl 1):147.
  • Callagher P, Mitchell D, Bennett W, Addison-Jones R. Evaluating a fast-track diagnostic service for people suspected of having MND/ALS. British Journal of Neuroscience Nursing. 2009;5:322–5.
  • Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. Journal of the Neurological Sciences. 1996;139 (Suppl): 110–6.
  • Srinivasan J, Scala S, Jones R, Saleh F, Russell J. Inappropriate surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis. Muscle and Nerve. 2006;34: 359–60.
  • MND Association. The Impact of Familial Motor Neuron Disease. Information Sheet, No. P2. 2007. http://tinyurl.com/m2uhv4 (accessed 18 December 2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.